Follow
Hyun lee
Title
Cited by
Cited by
Year
Local structural elements in the mostly unstructured transcriptional activation domain of human p53
H Lee, KH Mok, R Muhandiram, KH Park, JE Suk, DH Kim, J Chang, ...
Journal of Biological Chemistry 275 (38), 29426-29432, 2000
3852000
A tripartite complex of suPAR, APOL1 risk variants and αvβ3 integrin on podocytes mediates chronic kidney disease
SS Hayek, KH Koh, ME Grams, C Wei, YA Ko, J Li, B Samelko, H Lee, ...
Nature medicine 23 (8), 945-953, 2017
1962017
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2
N Drayman, JK DeMarco, KA Jones, SA Azizi, HM Froggatt, K Tan, ...
Science 373 (6557), 931-936, 2021
1822021
MG53-induced IRS-1 ubiquitination negatively regulates skeletal myogenesis and insulin signalling
JS Yi, JS Park, YM Ham, N Nguyen, NR Lee, J Hong, BW Kim, H Lee, ...
Nature communications 4 (1), 2354, 2013
1732013
Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein− ligand X-ray structure and biological evaluation
AK Ghosh, J Takayama, KV Rao, K Ratia, R Chaudhuri, DC Mulhearn, ...
Journal of medicinal chemistry 53 (13), 4968-4979, 2010
1592010
Structure and function of the phosphothreonine-specific FHA domain
A Mahajan, C Yuan, H Lee, ESW Chen, PY Wu, MD Tsai
Science signaling 1 (51), re12-re12, 2008
1562008
Identification of novel small molecule inhibitors against NS2B/NS3 serine protease from Zika virus
H Lee, J Ren, S Nocadello, AJ Rice, I Ojeda, S Light, G Minasov, J Vargas, ...
Antiviral research 139, 49-58, 2017
1382017
Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV
H Lee, H Lei, BD Santarsiero, JL Gatuz, S Cao, AJ Rice, K Patel, ...
ACS chemical biology 10 (6), 1456-1465, 2015
1332015
Design of SARS-CoV-2 PLpro inhibitors for COVID-19 antiviral therapy leveraging binding cooperativity
Z Shen, K Ratia, L Cooper, D Kong, H Lee, Y Kwon, Y Li, S Alqarni, ...
Journal of medicinal chemistry 65 (4), 2940-2955, 2021
1192021
Probing the structural requirements of non-electrophilic naphthalene-based Nrf2 activators
AD Jain, H Potteti, BG Richardson, L Kingsley, JP Luciano, AF Ryuzoji, ...
European journal of medicinal chemistry 103, 252-268, 2015
952015
Diphosphothreonine-specific interaction between an SQ/TQ cluster and an FHA domain in the Rad53-Dun1 kinase cascade
H Lee, C Yuan, A Hammet, A Mahajan, ESW Chen, MR Wu, MI Su, ...
Molecular cell 30 (6), 767-778, 2008
892008
Rufomycin targets ClpC1 proteolysis in Mycobacterium tuberculosis and M. abscessus
MP Choules, NM Wolf, H Lee, JR Anderson, EM Grzelak, Y Wang, R Ma, ...
Antimicrobial agents and chemotherapy 63 (3), 10.1128/aac. 02204-18, 2019
862019
Identification of novel drug scaffolds for inhibition of SARS-CoV 3-Chymotrypsin-like protease using virtual and high-throughput screenings
H Lee, A Mittal, K Patel, JL Gatuz, L Truong, J Torres, DC Mulhearn, ...
Bioorganic & medicinal chemistry 22 (1), 167-177, 2014
672014
Airway epithelial cell-derived colony stimulating factor-1 promotes allergen sensitization
HG Moon, S Kim, JJ Jeong, SS Han, NN Jarjour, H Lee, ...
Immunity 49 (2), 275-287. e5, 2018
652018
Ginkgolic acid and anacardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases
Z Chen, Q Cui, L Cooper, P Zhang, H Lee, Z Chen, Y Wang, X Liu, L Rong, ...
Cell & Bioscience 11, 1-8, 2021
572021
Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CLpro
R Du, L Cooper, Z Chen, H Lee, L Rong, Q Cui
Antiviral research 190, 105075, 2021
572021
Targeting SARS‐CoV‐2 viral proteases as a therapeutic strategy to treat COVID‐19
V Anirudhan, H Lee, H Cheng, L Cooper, L Rong
Journal of medical virology 93 (5), 2722-2734, 2021
472021
High-resolution structure of ClpC1-rufomycin and ligand binding studies provide a framework to design and optimize anti-tuberculosis leads
NM Wolf, H Lee, MP Choules, GF Pauli, R Phansalkar, JR Anderson, ...
ACS infectious diseases 5 (6), 829-840, 2019
472019
Reducing agents affect inhibitory activities of compounds: results from multiple drug targets
H Lee, J Torres, L Truong, R Chaudhuri, A Mittal, ME Johnson
Analytical biochemistry 423 (1), 46-53, 2012
452012
Hit-to-Lead: hit validation and assessment
KE Hevener, R Pesavento, JH Ren, H Lee, K Ratia, ME Johnson
Methods in Enzymology 610, 265-309, 2018
412018
The system can't perform the operation now. Try again later.
Articles 1–20